Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof

A non-alcoholic, composition technology, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., to achieve significant synergistic effect, significant effect, good curative effect

Inactive Publication Date: 2014-01-01
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the drugs on the market that have a therapeutic effect on fatty liver usually only target one target of NAFLD, or simply lower lipids, or improve insulin resistance. There is no drug that can simultaneously affect the upper, middle and lower stages of the pathogenesis of NAFLD (i.e., lipid absorption, lipid metabolism, and lipid excretion)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof
  • Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof
  • Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Preparation of tablets comprising a combination of curcumin and berberine

[0039] (1) The weight percent of curcumin and berberine in the composition can be, but not limited to:

[0040]

[0041] (2) Select the ratio of curcumin: berberine = 67:33, 60:40, 50:50, 40:60, 33:67 to form the tablet formula in Table 1 below and prepare corresponding tablets:

[0042] Table 1.

[0043]

[0044]

[0045] Tablet preparation method:

[0046] ①Weigh the prescribed amount of curcumin (purchased from Zhengzhou Xingyao Technology Co., Ltd.) and berberine hydrochloride (purchased from Sichuan Weikeqi Biotechnology Co., Ltd.) respectively, pass through 100 mesh sieves, and then mix according to the method of equal increments for later use ;

[0047] ②According to the tablet prescription in Table 1, weigh the prescription amount of other auxiliary materials except 5% povidone K-30 and magnesium stearate and mix them for subsequent use;

[0048] ③ Add an appropriate amoun...

Embodiment 2

[0054] Preparation of turmeric extract containing curcumin as the main medicinal component and berberine as the main Tablets of the composition of the Coptis chinensis extract as the medicinal ingredient

[0055] (1) Preparation of turmeric extract with curcumin as the main active ingredient and berberine as the main active ingredient in Coptis chinensis extract

[0056] Turmeric extract with curcumin as the main medicinal ingredient: crush 50kg of dried rhizomes of turmeric (produced in Sichuan), add 75% (volume percentage) ethanol aqueous solution at a liquid-to-solid ratio of 10:1, soak at room temperature for 24 hours, and pour out the ethanol aqueous solution , re-add new 75% (volume percent) ethanol aqueous solution and soak for 24 hours again, repeat 3 times, combine the ethanol aqueous solution, concentrate under reduced pressure to remove the ethanol aqueous solution, and obtain turmeric extract (powder, dry Back weight: 8.5kg), according to high performance liqui...

Embodiment 3

[0082] Experiments on pharmacological activity of compositions comprising curcumin and berberine

[0083] ①Therapeutic effect on fatty liver:

[0084] Experimental animals: SD rats, 120, ♂, clean grade, initially 6-8 weeks old, 100-150g. Feed with normal or high-fat diet. Fatty liver model was induced by feeding high-fat diet for 10 weeks.

[0085] Experimental grouping: normal rat group (10 rats), fatty liver model group (10 rats), fatty liver model curcumin intervention group (100mg / kg.d) (10 rats), fatty liver model berberine intervention group (100mg / kg.d) (10 rats), fatty liver model composition intervention group ((curcumin + berberine) mg / kg.d: (100+100), (50+50), (100+50), (50+100), (90+60), (60+90), (120+40), (40+120) mg / kg.d) (10 rats in the composition intervention group for each dose). Each group was administered for 10 weeks and administered by intragastric administration.

[0086] Among them, curcumin was purchased from Zhengzhou Xingyao Technology Co., L...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition used for preventing and treating the non-alcoholic fatty liver disease. The pharmaceutical composition includes curcumin and berberine or includes a turmeric extract with curcumin as a main effective component and a coptis extract with berberine as a main effective component. The composition provided by the invention has a good synergistic effect and exerts an excellent curative effect on the non-alcoholic fatty liver disease; and compared with a single component of the composition, the pharmaceutical composition has more substantial prevention and treatment effects.

Description

technical field [0001] The present application relates to a pharmaceutical composition. Specifically, the application relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver and diseases related to abnormal lipid metabolism, and relates to the preparation of the pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver And use in medicines for diseases related to abnormal lipid metabolism, such as obesity, hyperlipidemia, hyperglycemia and diabetes. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by hepatic parenchymal steatosis and fat accumulation without a history of excessive alcohol consumption. With the development of social economy and the improvement of people's living standards, the incidence of NAFLD is increasing year by year, and it has become a common chronic liver disease that endangers human health. Global epide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K36/9066A61P1/16A61P3/04A61P3/06A61P3/10A61K31/12
Inventor 王伽伯肖小河匡双玉赵艳玲柏兆方臧清策马致洁鄢丹张萍
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com